ベングルスタットによる常染色体優性多発性嚢胞腎（ADPKD）の長期治療

基本情報

NCT ID

NCT04705051

ステータス

中止

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

24

治験依頼者名

Sanofi

概要

Primary Objective: -To determine the effect of early versus delayed treatment with venglustat on the total kidney volume (TKV) in participants at risk of rapidly progressive autosomal dominant polycystic kidney disease (ADPKD). Secondary Objective: * To determine the effect of early versus delayed treatment with venglustat on the renal function (estimated glomerular filtration rate \[eGFR\] \[Chronic Kidney Disease Epidemiology Collaboration {CKD-EPI} equation\]). * To characterize the safety profile of venglustat. * To evaluate the effect of venglustat on the lens by ophthalmological examination. * To evaluate the effect of venglustat on mood using Beck Depression Inventory-II (BDI-II).

対象疾患

介入

依頼者（Sponsor）